Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...

CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot. Polycystic liver disease is a rare genetic disorder characterized by the progressive growth of more ...

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...

Please provide your email address to receive an email when new articles are posted on . Diarrhea in cancer patients is common and can result from different treatments and toxicities. These include ...

- Patients on pasireotide (SOM230) LAR were 63% more likely to achieve full biochemical control than those on Sandostatin LAR, the current standard of care[1] - Acromegaly, a rare endocrine disorder ...

We describe an adult man who had hypophosphatemic osteomalacia for several years before an octreotide scan revealed a mesenchymal tumor in his left thigh. Moreover, subcutaneous administration of ...

Company Plans to Initiate Phase III Program in First Half of 2008 LEXINGTON, Mass., Nov. 28 -- Indevus Pharmaceuticals, Inc. today announced positive results from its Phase II octreotide implant trial ...

Viatris Inc's (NASDAQ: VTRS) Mylan is voluntarily recalling one lot of Octreotide Acetate Injection, 500 mcg/mL, packaged in a carton of ten 1mL syringes due to a product complaint of the presence of ...